Results from two recent studies suggest computer-aided detection for breast MRI may be closing in on true cancer detection.
Results from two recent studies suggest computer-aided detection for breast MRI may be closing in on true cancer detection.
Researchers from Penn Diagnostics, a breast MRI CAD company, and George Washington University tested the ONCAD system for contrast-enhanced MRI. They reviewed images of 102 biopsy-proven breast cancers and 131 cancer-free breasts from six major U.S. research institutions. The investigators found ONCAD could identify up to 96% of true malignancies.
In another study, researchers from New York University and Siemens Medical Solutions presented results of a computer classification system designed to improve breast MRI BI-RADS classification. Forty patients were included in this study. The investigators found the automated classification tool yielded more accurate BI-RADS classifications than three radiologists blinded to results. Both studies were released at the 2008 ARRS meeting.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.